NV, I agree with a lot of what you said. By saying the merger clearly comes across as a takeover by OnCore, I did not intend to be disrespectful of MM. I only meant he got out-maneuvered by a team which seems quite adept at this sort of thing. Most CEOs, even the brilliant ones, have their strong suits and not-so-strong suits. In any case, water under the bridge.
The new TKMR is by all accounts a more formidable company than the old TKMR. Over and above everything else, the new management team is well equipped to continually manage perceptions in the market to TKMR's benefit, which is no small thing, considering the inevitable long dry spells between clinical breakthroughs that are the bane of most biotechs -- the spells during which market manipulators have their way with the companies' stocks.